Beam TherapeuticsBEAM
About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Employees: 461
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
133% more call options, than puts
Call options by funds: $16.6M | Put options by funds: $7.11M
18% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 61
3.41% more ownership
Funds ownership: 90.8% [Q1] → 94.2% (+3.41%) [Q2]
3% less funds holding
Funds holding: 218 [Q1] → 212 (-6) [Q2]
14% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 42
26% less capital invested
Capital invested by funds: $2.45B [Q1] → $1.82B (-$632M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Scotiabank Greg Harrison 55% 1-year accuracy 11 / 20 met price target | 1%downside $24 | Sector Perform Initiated | 16 Oct 2024 |
RBC Capital Luca Issi 18% 1-year accuracy 4 / 22 met price target | 11%upside $27 | Sector Perform Reiterated | 19 Sept 2024 |
Stifel Benjamin Burnett 45% 1-year accuracy 5 / 11 met price target | 183%upside $69 | Buy Maintained | 11 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 48 / 132 met price target | 229%upside $80 | Buy Reiterated | 22 Aug 2024 |
JP Morgan Eric Joseph 54% 1-year accuracy 13 / 24 met price target | 97%upside $48 | Overweight Maintained | 7 Aug 2024 |